By carefully selecting cases and matching patient age to a large control group, we showed that this breast cancer disease model is representative of treatment outcomes when compared to current clinical trials and real-world data analyses, especially when compared to HR-positive or HER2-positive patient populations [25,26,27,28,29,30,31,32,33]. This evidence concerns the gene ERBB2 and breast carcinoma.